Compare Tempus AI (TEM) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tempus AI vs Xylem, Inc. — how do they compare? Tempus AI trades at $61.15 (market cap $11.67B), while Xylem, Inc. trades at $107.97 (market cap $25.41B). The key difference: Xylem, Inc. is far larger — about 2.2× Tempus AI's market cap, and Xylem, Inc. pays a 1.58% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| TEM | XYL | |
|---|---|---|
Market Cap | $11.67B | $25.41B |
Sector | Broad Market / Factor | Industrials |
52-Week High | $103.25 | $152.95 |
52-Week Low | $41.55 | $105.69 |
Enterprise Value | $12.30B | $27.18B |
Dividend Yield | — | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $64.29, down 0.51% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats despite negative profitability, with a P/S of 7.99 and P/B of 26.23. Recent catalysts include FDA clearance for an AI ECG product and a $9.5 million ARPA-H award for autonomous AI in cardiology (Business Wire, September 9, 2026).
Outlook remains positive given analyst consensus and growth in precision medicine, but risks include sustained losses, high valuation multiples, and cash burn. The consensus price target is $69.11, implying potential upside, though investors must weigh the company's unprofitability against its innovation pipeline and market position.
XYL trades at $108.81, up 2.95% today, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 10.59% net margin. Recent news highlights strategic acquisitions, a new CFO appointment, and a dividend declaration, supporting growth in water technology sectors. The stock shows resilience with revenue growth from $5.5B in 2022 to $9.04B in 2025, though it faces near-term resistance.
Outlook is cautiously optimistic with a consensus price target of $152.29 implying 40% upside, driven by margin expansion and AI-driven demand. Risks include execution of acquisitions and market volatility, but analyst sentiment leans buy/hold with low sell ratings. The stock presents a value opportunity for long-term investors focused on sustainable water solutions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
